THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a corporation organised under the laws of the State of Delaware, United States. It is an active reporting issuer with the U.S. Securities and Exchange Commission under Central Index Key 0000097745 and Commission file number 1-8002, with IRS Employer Identification Number 04-2209186 and principal executive offices at 168 Third Avenue, Waltham, Massachusetts 02451. Its most recent annual report on Form 10-K, for the financial year ended 31 December 2025, was filed on 26 February 2026, and its most recent quarterly report on Form 10-Q, for the period ended 27 June 2026, was filed on 31 July 2026.
The Florida document number 851304 carried on this profile is not the company’s charter number, and Florida is not its state of incorporation. It identifies a legacy record on the Florida Department of State’s corporate register, carrying neither the “P” prefix Florida applies to domestic profit corporations nor the “F” prefix it applies to foreign qualifications. The Florida corporate event file records, against that document number, corporate amendments filed on 24 June 1986 and 29 June 1987 and a name-change amendment filed on 14 November 2006 recording the name THERMO FISHER SCIENTIFIC INC. That 2006 name change tracks the registrant’s own change of name from Thermo Electron Corporation, which EDGAR records as its former name until 3 November 2006 and which followed completion, on 9 November 2006, of the merger under which a subsidiary of Thermo Electron Corporation merged into Fisher Scientific International Inc. The listed entity therefore pre-dates the 2006 combination under its earlier name. Florida’s public corporate master file records document number 851304 as an active foreign profit corporation (filing type FORP) whose state of incorporation is recorded as Delaware, with a file date of 15 December 1981, a status date of 14 November 2006, a registered agent in Tallahassee, Florida, and an annual report most recently filed on 21 April 2026. The date of 15 December 1981 stored on this profile is therefore the date on which the company qualified to do business in Florida as a foreign corporation, not the date of its Delaware incorporation; the filings reviewed do not state the date of the Delaware incorporation.
Thermo Fisher Scientific Inc. supplies laboratory instruments, reagents, consumables, software and outsourced services to customers in pharmaceutical and biotechnology companies, hospitals and clinical diagnostic laboratories, universities, research institutions and government agencies, as well as environmental, industrial, quality-control and process-control settings. The company reports its business in four segments. Life Sciences Solutions covers biosciences, genetic sciences and bioproduction reagents, instruments and consumables. Analytical Instruments covers chromatography and mass spectrometry, chemical analysis, and electron microscopy. Specialty Diagnostics covers clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics and a healthcare market channel. Laboratory Products and Biopharma Services covers laboratory products, a research and safety market channel, pharma services and clinical research. Products and services are sold under brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For the financial year ended 31 December 2025 the company reported consolidated revenues of USD 44,556 million, comprising product revenues of USD 25,965 million and service revenues of USD 18,592 million, together with consolidated GAAP operating income of USD 7,746 million and GAAP diluted earnings per share of USD 17.74. Consolidated revenues for the six months ended 27 June 2026 were USD 22,999 million. As of 31 December 2025 the company employed approximately 125,000 people worldwide on a consolidated basis, of whom approximately 59,000 were based in the Americas, approximately 44,000 in Europe, the Middle East and Africa, and approximately 22,000 in Asia-Pacific. During 2025 the company reported revenue growth in the pharma and biotech market, a decline in the academic and government market, growth in the industrial and applied market, and flat revenues in the diagnostics and healthcare market.
The common stock of Thermo Fisher Scientific Inc., of USD 1.00 par value, is listed on the New York Stock Exchange under the ticker symbol TMO, and thirteen series of the company’s notes are also listed on that exchange. As of 31 January 2026 there were 371,484,244 shares of common stock outstanding. Two recent transactions are recorded in the filings: on 1 September 2025 the company acquired the filtration and separation business of Solventum Corporation, reported at USD 3,939 million in cash, into the Life Sciences Solutions segment; and on 24 March 2026 it acquired Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, for total consideration reported at USD 9,098 million, into the Laboratory Products and Biopharma Services segment.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a listed company whose common stock trades on the New York Stock Exchange under the symbol TMO. There is no register of all of its shareholders in the public domain: only holders crossing the U.S. beneficial-ownership reporting threshold of 5 per cent, and the holdings of directors and executive officers, are disclosed. As of 31 January 2026 the company had 371,484,244 shares of common stock outstanding.
The beneficial-ownership table in the definitive proxy statement filed on 7 April 2026, stated as of 28 February 2026, identifies two holders of more than 5 per cent of the common stock. The Vanguard Group was shown with 32,977,462 shares, or 8.87 per cent, on the basis of a Schedule 13G/A it filed on 13 February 2024. BlackRock, Inc. was shown with 28,329,861 shares, or 7.62 per cent, on the basis of a Schedule 13G it filed on 8 February 2024, reporting sole voting power over 25,498,677 shares and sole dispositive power over 28,329,861 shares.
That position has since changed. In a Schedule 13G/A filed on 27 March 2026 (amendment number 10, event date 13 March 2026) The Vanguard Group reported beneficial ownership of nil shares and 0.0 per cent, stating that following an internal realignment on 12 January 2026 certain of its subsidiaries and business divisions would report beneficial ownership separately. Vanguard Capital Management LLC then filed a Schedule 13G on 30 April 2026, with an event date of 31 March 2026, reporting 28,008,822 shares, or 7.53 per cent, with sole voting power over 3,728,006 shares and sole dispositive power over 28,008,822 shares, held together with named Vanguard affiliates. No Schedule 13D has been filed in respect of the company’s common stock by any person.
All current directors and executive officers as a group, 19 individuals, held 1,207,932 shares on a beneficial-ownership basis as of 28 February 2026, which the proxy statement reports as less than one per cent of the class. No individual director or executive officer was reported at one per cent or more.
Ultimate beneficial ownership. No ultimate beneficial owner can be identified for Thermo Fisher Scientific Inc. The largest reported holders are institutional asset managers holding on behalf of funds and clients, and the largest single reported position, 8.87 per cent, is well below any customary beneficial-ownership control threshold. No natural person is disclosed in any filing reviewed as holding, directly or indirectly, an interest at or above 25 per cent, and no complete ownership chain exists from which an effective percentage could be calculated. Ultimate beneficial ownership is therefore not identifiable from public sources.
Data availability. Major shareholders only. United States disclosure for a listed issuer covers holders above the 5 per cent reporting threshold and the holdings of directors and executive officers; it does not produce a complete shareholder register, and the absence of further names is not evidence that no other shareholders exist. The percentages above are those stated in the filings themselves; the five shareholder rows held in the underlying provider feed for this profile are not a shareholder register and the percentages attached to them do not reconcile to the share count reported by the company.
Sources.
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. definitive proxy statement (DEF 14A), filed 7 April 2026 — https://www.sec.gov/Archives/edgar/data/97745/000119312526144585/d66426ddef14a.htm (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Schedule 13G/A filed by The Vanguard Group, 27 March 2026 — https://www.sec.gov/Archives/edgar/data/97745/000010290926002494/primary_doc.xml (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Schedule 13G filed by Vanguard Capital Management LLC, 30 April 2026 — https://www.sec.gov/Archives/edgar/data/97745/000210011926001108/primary_doc.xml (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. annual report on Form 10-K for 2025, filed 26 February 2026 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm (retrieved 30 September 2026)
Data-provider feed — rows as supplied to Zavia for Florida Department of State — Sunbiz, including entries the profile above does not cover. These rows are not a verbatim copy of the register: they have been found to duplicate the same person under different spellings and to keep a status of Active after an appointment ended. Where they disagree with the profile above, the profile is the checked version.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Vanguard Group Inc | 17.6% | Florida Department of State — Sunbiz | |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 4.8% | Florida Department of State — Sunbiz | |
| iShares Trust-iShares Core S&P 500 ETF | 2.5% | Florida Department of State — Sunbiz | |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 2.5% | Florida Department of State — Sunbiz | |
| NEW PERSPECTIVE FUND | 1.1% | Florida Department of State — Sunbiz |
Officers
5
Directors and officers of THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a Delaware corporation whose board is elected annually. At the annual meeting held on 20 May 2026, eleven directors were elected to serve until the 2027 annual meeting: Marc N. Casper, Nelson J. Chai, Ruby R. Chandy, C. Martin Harris, Tyler Jacks, Jennifer M. Johnson, R. Alexandra Keith, Karen S. Lynch, Debora L. Spar, Scott M. Sperling and Dion J. Weisler. James C. Mullen, a director until that meeting, did not stand for re-election, and the board was reduced from twelve to eleven members with effect from the 2026 annual meeting. Marc N. Casper is the only member of management serving on the board.
The annual report on Form 10-K filed on 26 February 2026 identified eight executive officers as of that date: Marc N. Casper (Chairman, President and Chief Executive Officer), Stephen Williamson (Senior Vice President and Chief Financial Officer), Michel Lagarde (Executive Vice President and Chief Operating Officer), Frederick M. Lowery (Executive Vice President), Gianluca Pettiti (Executive Vice President), Michael D. Shafer (Executive Vice President), Lisa P. Britt (Senior Vice President and Chief Human Resources Officer) and Thomas B. Shropshire (Senior Vice President and General Counsel). Taking the board and the executive-officer list together, and counting Marc N. Casper once, nineteen distinct office-holders are verified in the filings reviewed — the same figure the proxy statement uses for “all current directors and executive officers as a group”.
Recent officer changes.
- Effective 1 March 2026, Marc N. Casper ceased to hold the title of President and became Chairman and Chief Executive Officer, and Gianluca Pettiti was promoted from Executive Vice President to President and Chief Operating Officer (Current Report on Form 8-K dated 12 January 2026).
- Michel Lagarde, Executive Vice President and Chief Operating Officer since 2021, left the company on 31 March 2026, and Frederick M. Lowery, an Executive Vice President since 2024, left on 28 February 2026 (same Form 8-K).
- James C. Mullen ceased to be a director at the annual meeting held on 20 May 2026, having not stood for re-election (Form 8-K, Item 5.07, filed 26 May 2026).
Data availability. Partial. Delaware does not publish directors or officers on the state corporate register, so the office-holder record for this company comes from federal securities filings rather than from a company registry: the board is evidenced by the annual-meeting voting results, and the executive-officer list by the Form 10-K. Nationality is not disclosed for any director or officer in any of the filings reviewed and is recorded here as “Not disclosed”; country of residence is likewise not disclosed, and the address given for every director and executive officer in the proxy statement is the company’s own office at 168 Third Avenue, Waltham, Massachusetts, which is a correspondence address and not a residential one. No date of birth is published; the Form 10-K states ages for executive officers only. Appointment dates for directors are not stated in the filings reviewed other than through successive annual-meeting results.
One state register does carry an office-holder list for this company. Florida’s public corporate master file holds the company’s foreign-qualification record under document number 851304, and the officer list from its most recently filed annual report, filed on 21 April 2026, names six office-holders: Marc Casper as chairman and C. Martin Harris, Jennifer M. Johnson, James Mullen, Debora L. Spar and Dion J. Weisler as directors. All six were genuine board members at that date; James Mullen stood down at the annual meeting the following month. That state record is consistent with the securities filings, and it is not the source of the rows described next.
The five officer rows held in the underlying provider feed for this profile are not the officer list and should not be read as one. They are five of a stated 62 rows, all carry the single job title “Governor” — which is not an office used by this Delaware corporation — all are flagged active, and none carries an appointment or resignation date. Two of the five, R. Alexandra Keith and Nelson J. Chai, are genuine current directors but are mis-titled. Jim P. Manzi was elected a director at the annual meeting of 18 May 2022 but was not among the nominees elected on 24 May 2023, so his board service ended more than three years before the feed recorded him as active. Of the remaining two names, one appears in no filing made by this company, and the other, Jonas Svedlund, appears in the company’s filings only as a lawyer copied on correspondence annexed to the 2023 tender-offer documents for Olink Holding AB (publ), not as an officer of Thermo Fisher Scientific Inc.
Sources.
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. Current Report on Form 8-K, Item 5.07 (annual meeting held 20 May 2026), filed 26 May 2026 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000117/tmo-20260520.htm (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. Current Report on Form 8-K, Item 5.02, filed 12 January 2026 — https://www.sec.gov/Archives/edgar/data/97745/000114036126000871/ef20062683_8k.htm (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. annual report on Form 10-K for 2025, section “Information about Our Executive Officers”, filed 26 February 2026 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. definitive proxy statement (DEF 14A), filed 7 April 2026 — https://www.sec.gov/Archives/edgar/data/97745/000119312526144585/d66426ddef14a.htm (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. Current Reports on Form 8-K, Item 5.07, filed 19 May 2022 and 26 May 2023 — https://www.sec.gov/Archives/edgar/data/97745/000009774522000032/tmo-20220518.htm and https://www.sec.gov/Archives/edgar/data/97745/000009774523000042/tmo-20230524.htm (retrieved 30 September 2026)
Data-provider feed — rows as supplied to Zavia for Florida Department of State — Sunbiz, including entries the profile above does not cover. These rows are not a verbatim copy of the register: they have been found to duplicate the same person under different spellings and to keep a status of Active after an appointment ended. Where they disagree with the profile above, the profile is the checked version.
Group Structure
Group structure of THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is the parent company of its own group. It is a listed Delaware corporation with no parent and no controlling shareholder, so there is no immediate or ultimate parent to report. The authoritative list of its subsidiaries is Exhibit 21 to its annual report on Form 10-K for the year ended 31 December 2025, filed on 26 February 2026, which names 1,269 entities. Exhibit 21 states each entity’s name and state or jurisdiction of organisation only; it does not state ownership percentages, registration numbers, or the position of each entity within the ownership chain, so the internal shape of the group cannot be reconstructed from it.
By jurisdiction of organisation, the Exhibit 21 list is led by Delaware (369 entities), England (156), the Netherlands (55), Luxembourg (55), Barbados (49), Germany (42), China (36), Sweden (30), Canada (28) and France (22), with the remainder spread across more than forty further jurisdictions and sixteen further U.S. states. That is the disclosure position as at the 2025 financial year end.
Recent structural changes. On 1 September 2025 the company acquired the filtration and separation business of Solventum Corporation, reported at USD 3,939 million in cash, which was placed in the Life Sciences Solutions segment. On 24 March 2026 it acquired Clario Holdings, Inc. for total consideration reported at USD 9,098 million, placed in the Laboratory Products and Biopharma Services segment. Also during 2026 it acquired two proteomics software companies, one in the United States and one in Germany, into the Analytical Instruments segment. Because Exhibit 21 to the 2025 Form 10-K was drawn up before the 2026 transactions completed, the legal entities acquired in 2026 are not yet reflected in it.
Data availability. Subsidiaries only, and partial. The United States does not publish a corporate-ownership register: for an SEC-reporting issuer the subsidiary list comes from Exhibit 21, which carries no ownership percentages and no registration numbers, and which may omit subsidiaries that are not significant in the aggregate. No ownership percentage is therefore stated for any entity in this group, and the absence of a percentage must not be read as anything other than non-disclosure.
The corporate tree held in the underlying provider feed for this profile contains 1,014 nodes and is not reproduced here, because an audit of it against Exhibit 21 found material defects. 815 of the 1,014 node names correspond to an entity named in Exhibit 21; 199 do not. The tree is heavily flattened: 416 of the 1,014 nodes sit as direct children of the parent, which Exhibit 21 does not support. Identifier quality is poor: 260 nodes, about 26 per cent, carry a placeholder identifier prefixed with a hash sign rather than a registration number, while others carry a tax identifier in the registration-number field rather than a company registration number — 17 French nodes carry a 14-digit SIRET establishment number in place of the 9-digit SIREN, 14 Mexican nodes carry an RFC tax code, and several Hungarian nodes carry an 11-digit tax number in place of the court registration number. At least twelve nodes are branches rather than companies, identifiable from their own names: Norwegian NUF registrations, Swedish and Danish “filial” registrations, a German “Zweigniederlassung”, a Slovak “organizačná zložka”, a Spanish “sucursal” and a Taiwan branch; two of those branches appear twice under two different national numbers. Two entities whose names state that they are in liquidation are shown as live. Twenty-five names occur more than once in the tree under different identifiers. The parent itself appears twice, is given a Massachusetts registration number although it is a Delaware corporation, and is also shown as a subsidiary of itself through a Swedish registration that is a branch of the U.S. company; its own former name, Thermo Electron Corporation, likewise appears beneath it as though it were a separate subsidiary. One Mexican company is assigned the country code of the Federated States of Micronesia.
The audit also found nodes that belong to entirely different companies. The clearest is CSL Behring Lengnau AG, shown in the feed as a direct subsidiary with the Swiss identifier CHE-270.558.484: that entity is disclosed in the annual report of CSL Limited as a wholly owned controlled entity of CSL Limited incorporated in Switzerland, and it does not appear in Thermo Fisher’s Exhibit 21. Others that appear as direct subsidiaries with no support in Exhibit 21 include INZULU MINING CO (PTY) LTD, a South African mining company; JOYWEL XPORTERS PRIVATE LIMITED, an Indian export company; KFx Fuel Partners, L.P., a Wyoming limited partnership; a node recorded only as HUGHES CHRISTENEN in the United Arab Emirates against a placeholder identifier; and a node named as an employees’ federal credit union, which is a member-owned mutual body and cannot be a corporate subsidiary. Two nodes named for Solventum entities were examined and are recorded here as unresolved rather than foreign: Thermo Fisher did acquire Solventum’s filtration and separation business on 1 September 2025, but neither node appears in Thermo Fisher’s Exhibit 21, and one of them, Solventum Purification, S. de R.L. de C.V., is still named in Solventum Corporation’s own Exhibit 21 to its Form 10-K for the year ended 31 December 2025.
Sources.
- U.S. Securities and Exchange Commission, Exhibit 21 (Subsidiaries of the Registrant) to Thermo Fisher Scientific Inc.’s annual report on Form 10-K for 2025, filed 26 February 2026 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/q4202510-kex21sublist.htm (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Thermo Fisher Scientific Inc. quarterly report on Form 10-Q for the period ended 27 June 2026, filed 31 July 2026 — https://www.sec.gov/Archives/edgar/data/97745/000009774526000144/tmo-20260627.htm (retrieved 30 September 2026)
- U.S. Securities and Exchange Commission, Exhibit 21 to Solventum Corporation’s annual report on Form 10-K for 2025, filed 27 February 2026 — https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/a202510-kexhibit21.htm (retrieved 30 September 2026)
- CSL Limited, Annual Report 2024, controlled entities disclosure — https://investors.csl.com/annualreport/2024/150/ (retrieved 30 September 2026)
Data-provider feed — rows as supplied to Zavia for Florida Department of State — Sunbiz, including entries the profile above does not cover. These rows are not a verbatim copy of the register: they have been found to duplicate the same person under different spellings and to keep a status of Active after an appointment ended. Where they disagree with the profile above, the profile is the checked version.
THERMO FISHER SCIENTIFIC INC.
United States
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does THERMO FISHER SCIENTIFIC INC. do?
Thermo Fisher Scientific Inc. supplies laboratory instruments, reagents, consumables and software, together with outsourced pharmaceutical development, manufacturing and clinical-research services. It reports four segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services. It is a Delaware corporation with principal executive offices at 168 Third Avenue, Waltham, Massachusetts 02451. The Florida document number 851304 on this profile is a legacy Florida registration record renamed to THERMO FISHER SCIENTIFIC INC. on 14 November 2006, not the company's charter number; Delaware is the state of incorporation.
Who owns THERMO FISHER SCIENTIFIC INC.?
Widely held listed company; only holders above the 5 per cent reporting threshold are disclosed. The proxy statement filed 7 April 2026, stated as of 28 February 2026, showed The Vanguard Group at 32,977,462 shares (8.87 per cent) and BlackRock, Inc. at 28,329,861 shares (7.62 per cent). The Vanguard Group subsequently reported 0.0 per cent in a Schedule 13G/A filed 27 March 2026 following an internal realignment, and Vanguard Capital Management LLC reported 28,008,822 shares (7.53 per cent) in a Schedule 13G filed 30 April 2026. No Schedule 13D has been filed on the common stock.
Who is THERMO FISHER SCIENTIFIC INC.'s UBO (Ultimate Beneficial Owner)?
No ultimate beneficial owner is identifiable. The largest disclosed holders are institutional asset managers holding on behalf of funds and clients; the largest reported position is 8.87 per cent, and no natural person is disclosed in any filing reviewed as holding 25 per cent or more, directly or indirectly. No complete ownership chain exists from which an effective percentage could be calculated.
What is THERMO FISHER SCIENTIFIC INC.'s company registration number?
THERMO FISHER SCIENTIFIC INC.'s registration number is 851304, filed with Florida Department of State — Sunbiz in United States. Its current status on the register is active.
Is THERMO FISHER SCIENTIFIC INC. still an active company?
THERMO FISHER SCIENTIFIC INC.'s status on Florida Department of State — Sunbiz is listed as active.
When was THERMO FISHER SCIENTIFIC INC. incorporated?
THERMO FISHER SCIENTIFIC INC. was incorporated on 15 December 1981, according to Florida Department of State — Sunbiz.
What is THERMO FISHER SCIENTIFIC INC.'s registered address?
The registered address on file for THERMO FISHER SCIENTIFIC INC. is WALTHAM, United States.
What is THERMO FISHER SCIENTIFIC INC.'s revenue?
Consolidated revenues were USD 44,556 million for the year ended 31 December 2025 (2024: USD 42,879 million), with consolidated GAAP operating income of USD 7,746 million and GAAP diluted earnings per share of USD 17.74. Consolidated revenues for the six months ended 27 June 2026 were USD 22,999 million. The company employed approximately 125,000 people worldwide as of 31 December 2025.
Is THERMO FISHER SCIENTIFIC INC. listed on a stock exchange?
Listed on the New York Stock Exchange under the ticker TMO (common stock, USD 1.00 par value), together with thirteen series of notes. SEC Commission file number 1-8002; Central Index Key 0000097745. There were 371,484,244 shares of common stock outstanding as of 31 January 2026.
Who are the officers/directors of THERMO FISHER SCIENTIFIC INC.?
Eleven directors were elected at the annual meeting held on 20 May 2026: Marc N. Casper, Nelson J. Chai, Ruby R. Chandy, C. Martin Harris, Tyler Jacks, Jennifer M. Johnson, R. Alexandra Keith, Karen S. Lynch, Debora L. Spar, Scott M. Sperling and Dion J. Weisler. James C. Mullen did not stand for re-election. The Form 10-K filed 26 February 2026 listed eight executive officers. Nineteen distinct office-holders are verified in total. Effective 1 March 2026 Marc N. Casper became Chairman and Chief Executive Officer and Gianluca Pettiti became President and Chief Operating Officer. Nationality is not disclosed for any director or officer.
Does THERMO FISHER SCIENTIFIC INC. have a parent company or subsidiaries?
Thermo Fisher Scientific Inc. has no parent company and sits at the top of its own group. Exhibit 21 to its Form 10-K for the year ended 31 December 2025 names 1,269 subsidiaries, led by Delaware (369), England (156), the Netherlands (55), Luxembourg (55) and Barbados (49). Exhibit 21 states no ownership percentages and no registration numbers, so no ownership percentage is reported for any group entity.
Can Zavia monitor changes to THERMO FISHER SCIENTIFIC INC.'s ownership over time?
This profile reflects a point-in-time snapshot from Florida Department of State — Sunbiz. Zavia's monitoring API can track changes to THERMO FISHER SCIENTIFIC INC.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access THERMO FISHER SCIENTIFIC INC.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United States, so records like THERMO FISHER SCIENTIFIC INC.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Florida Department of State — Sunbiz and was last synced on 29 September 2026.